Provided by Tiger Fintech (Singapore) Pte. Ltd.

Fate Therapeutics

1.04
-0.0400-3.70%
Post-market: 1.040.00000.00%18:22 EDT
Volume:869.54K
Turnover:906.97K
Market Cap:119.22M
PE:-0.70
High:1.08
Open:1.08
Low:1.02
Close:1.08
Loading ...

BRIEF-Fate Therapeutics Reports New Employee Inducement Awards

Reuters
·
Yesterday

Valamehr Bahram, President and CEO, Reports Disposal of Common Shares of Fate Therapeutics Inc

Reuters
·
Yesterday

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Yesterday

Fate Therapeutics’ Phase 1 Study: A New Hope for Autoimmune Diseases

TIPRANKS
·
02 Aug

Fate Therapeutics Inc. Files Initial Statement of Beneficial Ownership; RedCo II Master Fund, L.P. Named as Beneficial Owner

Reuters
·
04 Jul

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
04 Jul

Cautious Outlook on Fate Therapeutics Amid Promising Data and Safety Concerns

TIPRANKS
·
02 Jul

Fate Therapeutics (FATE) Receives a Hold from TD Cowen

TIPRANKS
·
12 Jun

Cautious Hold Rating on Fate Therapeutics Amid Promising but Preliminary CAR-T Therapy Data

TIPRANKS
·
12 Jun

Barclays Sticks to Its Buy Rating for Fate Therapeutics (FATE)

TIPRANKS
·
12 Jun

Bank of America Securities Sticks to Their Hold Rating for Fate Therapeutics (FATE)

TIPRANKS
·
12 Jun

Fate Therapeutics Announces Promising Clinical Data for FT819 in Treating Severe Lupus, Expands Program to Address Multiple Autoimmune Diseases

Reuters
·
11 Jun

Press Release: Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

Dow Jones
·
31 May

Fate Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Director Matt Abernethy

Reuters
·
31 May

Fate Therapeutics Is Maintained at Neutral by Baird

Dow Jones
·
14 May

Fate Therapeutics price target lowered to $4 from $5 at Baird

TIPRANKS
·
14 May

TD Cowen Remains a Hold on Fate Therapeutics (FATE)

TIPRANKS
·
14 May

Fate Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
14 May

Fate Therapeutics Q1 EPS $(0.32) Beats $(0.38) Estimate, Sales $1.63M Beat $1.14M Estimate

Benzinga
·
14 May

BRIEF-Fate Therapeutics Reports First Quarter 2025 Financial Results And Business Updates

Reuters
·
14 May